Your browser doesn't support javascript.
loading
Evaluation of Interactions of Selected Olivacine Derivatives with DNA and Topoisomerase II.
Tylinska, Beata; Dobosz, Agnieszka; Spychala, Jan; Cwynar-Zajac, Lucja; Czyznikowska, Zaneta; Kuzniarski, Amadeusz; Gebarowski, Tomasz.
Afiliación
  • Tylinska B; Department of Organic Chemistry, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Dobosz A; Department of Basic Medical Sciences, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Spychala J; Department of Basic Medical Sciences, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Cwynar-Zajac L; Department of Basic Medical Sciences, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Czyznikowska Z; Department of Inorganic Chemistry, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Kuzniarski A; Department of Prosthetic Dentistry, Wroclaw Medical University, 50-425 Wroclaw, Poland.
  • Gebarowski T; Department of Basic Medical Sciences, Wroclaw Medical University, 50-556 Wroclaw, Poland.
Int J Mol Sci ; 22(16)2021 Aug 06.
Article en En | MEDLINE | ID: mdl-34445198
ABSTRACT
Olivacine and ellipticine are model anticancer drugs acting as topoisomerase II inhibitors. Here, we present investigations performed on four olivacine derivatives in light of their antitumor activity. The aim of this study was to identify the best antitumor compound among the four tested olivacine derivatives. The study was performed using CCRF/CEM and MCF-7 cell lines. Comet assay, polarography, inhibition of topoisomerase II activity, histone acetylation, and molecular docking studies were performed. Each tested compound displayed interaction with DNA and topoisomerase II, but did not cause histone acetylation. Compound 2 (9-methoxy-5,6-dimethyl-1-({[1-hydroxy-2-(hydroxymethyl)butan-2-yl]amino}methyl)-6H-pyrido[4,3-b]carbazole) was found to be the best candidate as an anticancer drug because it had the highest affinity for topoisomerase II and caused the least genotoxic damage in cells.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Elipticinas / Inhibidores de Topoisomerasa II / Antineoplásicos Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Polonia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Elipticinas / Inhibidores de Topoisomerasa II / Antineoplásicos Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Polonia